The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis

References

• Albert M, Williamson D, Muscedere J, Lauzier F, Rotstein C, Kanji S, Jiang X, Hall M, Heyland D. 2014. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: A randomized placebo controlled pilot trial (Cantreat study). Intensive Care Med. 40(9):1313–1322.
   PubMed Web of Science ®Google Scholar
• Ali KH, Melillo A, Leonard S, Asthana D, Woolger J, Wolfson A, McDaniel HR, Lewis JE. 2012. An open-label, randomized clinical trial to assess the immunomodulatory activity of a novel oligosaccharide compound in healthy adults. Funct Foods Health Dis. 2(7):265–279.
   Google Scholar
• Allizond V, Scutera S, Rossi S, Musso T, Crocilla C, Cavalla P, Trebini C, Marra ES, Cuffini AM, Banche G. 2015. Polymorphonuclear cell functional impairment in relapsing remitting multiple sclerosis patients: preliminary data. PLoS One. 10(6):e0131557.
   PubMed Web of Science ®Google Scholar
• Andreadou E, Kemanetzoglou E, Brokalaki C, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E. 2013. Demyelinating disease following anti-TNFA treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med. 2013:671935.
   PubMedGoogle Scholar
• Anthony RS, McKelvie ND, Craig JI, Parker AC. 1998. Fas antigen (cd95) expression in peripheral blood progenitor cells from patients with leukaemia and lymphoma. Leuk Lymphoma. 30(5-6):449–458.
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 4(11):1116–1122.
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. 2010. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 16(9):703–712.
   PubMed Web of Science ®Google Scholar
• Bang MH, Van Riep T, Thinh NT, Song L. H, Dung TT, Van Truong L, Van Don L, Ky TD, Pan D, Shaheen M. 2010. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. Anticancer Res. 30(12):5145–5151.
   PubMed Web of Science ®Google Scholar
• Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. 1988. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand. 78(4):318–323.
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Malucchi S, Capobianco M, Manzardo E, Guastamacchia G, Milano E, Audano L, Mutani R. 1999. Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. J Interferon Cytokine Res. 19(6):575–581.
   PubMed Web of Science ®Google Scholar
• Calder PC. 2011. Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol. 668 (Suppl 1):S50–S58.
   PubMedGoogle Scholar
• Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, et al. 2014. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord. 3(2):227–236.
   PubMed Web of Science ®Google Scholar
• Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. 1996. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr. 63(1):116–122.
   PubMed Web of Science ®Google Scholar
• Cholujova D, Jakubikova J, Czako B, Martisova M, Hunakova L, Duraj J, Mistrik M, Sedlak J. 2013. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer Immunol Immunother. 62(3):437–445.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. 2008. Multiple sclerosis. Lancet. 372(9648):1502–1517.
   PubMed Web of Science ®Google Scholar
• Compston A, Zajicek J, Sussman J, Webb A, Hall G, Muir D, Shaw C, Wood A, Scolding N. 1997. Glial lineages and myelination in the central nervous system. J Anatomy. 190(2):161–200.
   PubMedGoogle Scholar
• Cui S, Hassan RY, Heintz-Buschart A, Bilitewski U. 2016. Regulation of Candida albicans interaction with macrophages through the activation of hog pathway by genistein. Molecules. 21(2):162
   PubMed Web of Science ®Google Scholar
• Damal K, Stoker E, Foley JF. 2013. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics. 7:247–258.
   PubMedGoogle Scholar
• del Barco DG, Montero E, Coro-Antich RM, Brown E, Suarez-Alba J, Lopez L, Subiros N, Berlanga J. 2011. Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis. Restor Neurol Neurosci. 29(4):243–252.
   PubMed Web of Science ®Google Scholar
• Dykman KD, Dykman RA. 1998. Effect of nutritional supplements on attentional-deficit hyperactivity disorder. Integr Physiol Behav Sci. 33(1):49–60.
   PubMed Web of Science ®Google Scholar
• Finsen B, Antel J, Owens T. 2002. TNF alpha: Kill or cure for demyelinating disease? Mol Psychiatry. 7(8):820–821.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez O, Romero-Rodriguez R, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A. 2009. Epidermal growth factor induces the progeny of subventricular zone type b cells to migrate and differentiate into oligodendrocytes. Stem Cells. 27(8):2032–2043.
   PubMed Web of Science ®Google Scholar
• Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, et al. 2012. Cause of death in MS: Long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNbeta-1b study. BMJ Open. 2(6):e001972.
   PubMed Web of Science ®Google Scholar
• Heidary M, Rakhshi N, Pahlevan Kakhki M, Behmanesh M, Sanati MH, Sanadgol N, Kamaladini H, Nikravesh A. 2014. The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients. J Neurol Sci. 343(1-2):41–45.
   PubMed Web of Science ®Google Scholar
• Hofman FM, Hinton DR, Johnson K, Merrill JE. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med. 170(2):607–612.
   PubMed Web of Science ®Google Scholar
• Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK. 2003. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity. 36(3):133–141.
   PubMed Web of Science ®Google Scholar
• Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. 2012. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 18(8):1144–1151.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. 1993. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 69(4):415–429.
   PubMed Web of Science ®Google Scholar
• Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. 2009. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complement Ther Med. 17(4):216–223.
   PubMed Web of Science ®Google Scholar
• Lewis JE, Atlas SE, Higuera OL, Fiallo A, Rasul A, Farooqi A, Kromo O, Lantigua LA, Tiozzo E, Woolger JM, et al. 2018. The effect of a hydrolyzed polysaccharide dietary supplement on biomarkers in adults with nonalcoholic fatty liver disease. Evid Based Complement Alternat Med. 2018:1751583
   PubMed Web of Science ®Google Scholar
• Lewis JE, McDaniel HR, Agronin ME, Loewenstein DA, Riveros J, Mestre R, Martinez M, Colina N, Abreu D, Konefal J, et al. 2013. The effect of an aloe polymannose multinutrient complex on cognitive and immune functioning in Alzheimer's disease. J Alzheimers Dis. 33(2):393–406.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. 2011. IL-2 family cytokines: new insights into the complex roles of il-2 as a broad regulator of t helper cell differentiation. Curr Opin Immunol. 23(5):598–604.
   PubMed Web of Science ®Google Scholar
• Livingston T, Fay M, Iyer R, Wells W, Pill MW. 2016. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs. J Manag Care Spec Pharm. 22(12):1385–1391.
   PubMed Web of Science ®Google Scholar
• Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. 2003. Cytokine profile in patients with multiple sclerosis following vitamin d supplementation. J Neuroimmunol. 134(1-2):128–132.
   PubMed Web of Science ®Google Scholar
• Maimone D, Gregory S, Arnason BG, Reder AT. 1991. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 32(1):67–74.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. 2010. Interleukin-2 receptor signaling at the interface between tolerance and immunity. Immunity. 33(2):153–165.
   PubMed Web of Science ®Google Scholar
• McCarty MF. 1997. Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans. Med Hypotheses. 48(3):245–251.
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 50(1):121–127.
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol. 149(11):3753–3758.
   PubMed Web of Science ®Google Scholar
• Montgomery S, Hillert J, Bahmanyar S. 2013. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 20(8):1153–1160.
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. 1995. Functional expression of fas antigen (cd95) on hematopoietic progenitor cells. Blood. 86(3):883–889.
   PubMed Web of Science ®Google Scholar
• Nagata S, Golstein P. 1995. The fas death factor. Science. 267(5203):1449–1456.
   PubMed Web of Science ®Google Scholar
• Nelson RE, Xie Y, DuVall SL, Butler J, Kamauu AW, Knippenberg K, Schuerch M, Foskett N, LaFleur J. 2015. Multiple sclerosis and risk of infection-related hospitalization and death in us veterans. Int J MS Care. 17(5):221–230.
   PubMedGoogle Scholar
• Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, Van Hecke W, Frijlink DW, Wattjes MP, Consortium PMLiDMP. 2015. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 372(15):1474–1476.
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, Chamorro B, Diez-Tejedor E. 2012. TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate or natalizumab. BMC Neurol. 12(1):95.
   PubMedGoogle Scholar
• Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA. 1992. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by FAS antigen engagement. Cell Immunol. 140(1):197–205.
   PubMed Web of Science ®Google Scholar
• Perfetto SP, Ambrozak D, Nguyen R, Chattopadhyay P, Roederer M. 2006. Quality assurance for polychromatic flow cytometry. Nat Protoc. 1(3):1522–1530.
   PubMed Web of Science ®Google Scholar
• Petursdottir DH, Olafsdottir I, Hardardottir I. 2002. Dietary fish oil increases tumor necrosis factor secretion but decreases interleukin-10 secretion by murine peritoneal macrophages. J Nutr. 132(12):3740–3743.
   PubMed Web of Science ®Google Scholar
• Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Torres-Sanchez ED, Sorto-Gomez TE, Cruz-Ramos JA, Orozco-Avina G, Celis de la Rosa AJ. 2013. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev. 2013:709493
   PubMedGoogle Scholar
• Rezapour-Firouzi S, Arefhosseini SR, Mehdi F, Mehrangiz E-M, Baradaran B, Sadeghihokmabad E, Mostafaei S, Fazljou SMB, Torbati M-A, Sanaie S, Zamani F. 2013. Immunomodulatory and therapeutic effects of hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. Complement Ther Med. 21(5):473–480.
   PubMed Web of Science ®Google Scholar
• Rosenkranz T, Novas M, Terborg C. 2015. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 372(15):1476–1478.
   PubMed Web of Science ®Google Scholar
• Sachdeva N, Yoon HS, Oshima K, Garcia D, Goodkin K, Asthana D. 2007. Biochip array-based analysis of plasma cytokines in HIV patients with immunological and virological discordance. Scand J Immunol. 65(6):549–554.
   PubMed Web of Science ®Google Scholar
• Saheki K, Fujimori Y, Takemoto Y, Kakishita E. 2000. Increased expression of FAS (Apo-1, CD95) on CD34+ haematopoietic progenitor cells after allogeneic bone marrow transplantation. Br J Haematol. 109(2):447–452.
   PubMed Web of Science ®Google Scholar
• Scalabrino G, Galimberti D, Mutti E, Scalabrini D, Veber D, De Riz M, Bamonti F, Capello E, Mancardi GL, Scarpini E. 2010. Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Res. 1333:64–71.
   PubMed Web of Science ®Google Scholar
• Scalabrino G, Veber D, De Giuseppe R, Roncaroli F. 2015. Low levels of cobalamin, epidermal growth factor, and normal prions in multiple sclerosis spinal cord. Neuroscience. 298:293–301.
   PubMed Web of Science ®Google Scholar
• See DM, Cimoch P, Chou S, Chang J, Tilles J. 1998. The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome. Integr Physiol Behav Sci. 33(3):280–287.
   PubMed Web of Science ®Google Scholar
• Sharief MK, Hentges R. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 325(7):467–472.
   PubMed Web of Science ®Google Scholar
• Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, Kulakova O, Tchechonin V, Gurova O, Deomina T, et al. 2001. Randomized study of antibodies to IFN-G and TNF-A in secondary progressive multiple sclerosis. Mult Scler. 7(5):277–284.,.
   PubMedGoogle Scholar
• Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr, Shepard HM. 1985. Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science. 230(4728):943–945.
   PubMed Web of Science ®Google Scholar
• Tejera-Alhambra M, Casrouge A, de Andres C, Seyfferth A, Ramos-Medina R, Alonso B, Vega J, Fernandez-Paredes L, Albert ML, Sanchez RS. 2015. Plasma biomarkers discriminate clinical forms of multiple sclerosis. PLoS One. 10(6):e0128952
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleas F, Pedersen T, Bjornara B, et al. 2012. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol. 69(8):1044–1051. Omega
   PubMed Web of Science ®Google Scholar
• Valiathan R, Deeb K, Diamante M, Ashman M, Sachdeva N, Asthana D. 2014. Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of t cell maturation subsets in adults of South Florida. Immunobiology. 219(7):487–496.
   PubMed Web of Science ®Google Scholar
• van Kester MS, Bouwes Bavinck JN, Quint KD. 2015. PML in patients treated with dimethyl fumarate. N Engl J Med. 373(6):583–584.
   PubMedGoogle Scholar
• van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. 2013. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 368(17):1658–1659.
   PubMed Web of Science ®Google Scholar
• Vargas DL, Tyor WR. 2017. Update on disease-modifying therapies for multiple sclerosis. J Investig Med. 65(5):883–891.
   PubMed Web of Science ®Google Scholar
• Varki A, Cummings RD, Esko JD, Stanley P, Hart G, Aebi M, Darvill A, Kinoshita T, Packer NH, PJJ, et al. 2015. Essentials of glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
   Google Scholar
• Veldman FJ, Nair CH, Vorster HH, Vermaak WJ, Jerling JC, Oosthuizen W, Venter CS. 1999. Possible mechanisms through which dietary pectin influences fibrin network architecture in hypercholesterolaemic subjects. Thromb Res. 93(6):253–264.
   PubMed Web of Science ®Google Scholar
• Waters RS, Perry JS, Han S, Bielekova B, Gedeon T. 2018. The effects of interleukin-2 on immune response regulation. Math Med Biol. 35(1):79–119.
   PubMed Web of Science ®Google Scholar
• Winkelmann A, Loebermann M, Reisinger EC, Zettl UK. 2014. Multiple sclerosis treatment and infectious issues: Update 2013. Clin Exp Immunol. 175(3):425–438.
   PubMed Web of Science ®Google Scholar